Reddit Posts
$CMPS is on the rise! Get it while it's hot, forcasted to hit 50 this year!
Dude buy some $CMPS before it's too late!
Bullish News for Psychadelic Stocks? "FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs..."
Starting to DCA into a bunch of stocks tomorrow. Thoughts?
$KAYS- bid moving higher! Low float stock entering mushroom space! Seeking approval for manufacturing and distributing pysilocybin! Stocks like DRUG, MNMD CMPS have been ripping lately eyes on KAYS!
Would you like to play a Game???? Its called the ATM Dilution Watch … You win, you live to Degen another day… You don’t you go to the back of the nearest Wendy’s.
This is an explosive short squeeze opportunity - HUGE: CSE / HUGE: NASDAQ
Interesting email I received from an investment banker - HUGE: CSE. HUGE: NASDAQ - FSD Pharma
What’s your favorite Magic Mushroom Penny Stock? A few I’ve been looking into are FTRP, SEEL, CYBN, CMPS, GHRS, ATAI, MNMD.
Puts on CMPS until I see the MEGAdosing studies
Long Read, (Industry Knowledge) on a Medium/Long Term Hold, Compass Pathways PLC. (Ticker - CMPS, Exchange NASDAQ). My thoughts below would like to hear what others think.
Long Read, (Industry Knowledge) on a Medium/Long Term Hold, Compass Pathways PLC. (Ticker - CMPS, Exchange NASDAQ)
Compass Pathways (CMPS) Down, but had good results
Compass Pathways (CMPS) down a lot but had good results?
CMPS Annouces positive top line Phase 2B results. The Shroom Boom is here & is gearing up to look like Cannabis 2.0 Boom.
CMPS actually did it: Psilocybin works for depression.
$CMPS Discussion of hallucinogen legalization
CMPS November options have some on the highest IV in the entire market
Actual Shroom Boom Incoming - $CMPS DD - Train Leaving the Station
Shroom Boom Incoming - $CMPS DD - Train Leaving the Station
Shroom Boom Incoming - $CMPS DD - Train Leaving the Station
$MNMD MindMed 🍄 (November 2021 FDA Phase 2b Psychedelics sector catalyst )
$MNMD MindMed and the Psychedelics #ShroomBoom 🍄 (November 2021 Phase 2b sector catalyst)
50k (shares) CMPS YOLO (FDA trials due soon). Going up or down. Shroom Boom.
COMPASS Pathways is granted new US patent for crystalline psilocybin
CMPS to report trial results in early Nov (check out the wild option activity for them in Nov)
Magic Mushrooms Maybe biggest advance since Prozac
COMPASS Pathways $CMPS acquires IP portfolio of novel psychedelic compounds and prodrugs
$ATAI psychedelics getting ready to go apeshit.
Anyone watching Psychedelics Boom? 5 of the only Major exchange listed companies on the NYSE and Nasdaq
Anyone following the psychedelics boom? 5 of the only major exchange nasdaq and nyse companies below
Psychedelic Investing NO OTC edition
News Out Today! Under the radar, low float with patented psilocybin treatments. Silo Pharma (OTCQB: SILO)
Hot Sector, a Psychedelic Biopharma Enterprise with a Focus Toward New Science, Shareholder Value, Patented Tech on Psilocybin and Recently Announced Plans to Up-list to the NASDAQ
Hot Sector and Opportunity in a Psychedelic Biopharma Enterprise with a Focus Toward New Science, Shareholder Value and Recently Announced Plans to Up-list to the NASDAQ
May be a serious squeeze coming on MNMD
🚀🚀🚀🚀🚀🚀Maxim Group Initiates Coverage on COMPASS Pathways (NASDAQ:CMPS)💎💎💎💎💎💎💎💎💎
🚀🚀🚀Maxim Group Initiates Coverage on COMPASS Pathways (NASDAQ:CMPS)💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎💎🚀🚀🚀
Time to get into Compass Pathways $CMPS.
🍄 🍄 🍄 the case for Peter Thiel backed MNMD, COMPASS, ATAI, and alternatives in the upcoming #ShroomBoom in a $100bn+ industry 💎🤲
Which stocks do you predict will increase with increased adoption and sale of psychedelics?
Not a short squeeze but I think ET, TAP, CMPS, and SCR are all greats buys
ATAI-Life Sciences Purchases 140,000 $CMPS shares valued at $5,000,000 USD
$ATAI Purchases 140,000 $CMPS shares valued at $5,000,000 USD
This show just how helpful the FDA is willing to be when they see potential. This is clearly a huge step for scaling these therapies when they are approved. Breakthrough status for MDMA and psilocybin. Then the dominoes will hit LSD and 18MC! MNMD CMPS
$MNMD - the Future of Psychiatry and Mental Health
Does the "Shroom Boom" have strong investing potential?
Does the "Shroom Boom" have strong investing potential?
Does the "Shroom Boom" have strong investing potential?
CNBC: A psychedelic drug boom in mental health treatment comes closer to reality CMPS MNMD CLXPF ATAI by Eric Rosenbaum
While COMPASS Pathways ($CMPS) had, until recently, the industry’s largest market cap, MindMed ($MNMD) was considered by many as the overall psychedelic champion. That is until Peter Theil backed ATAI announced their listing. Suddenly there was a company that could match MindMed’s biggest strength.
My DD on Compass Pathways (psilocybin play)
What the heck is Compass Pathways (CMPS) planning?
MNMD (MindMed) to be traded on NASDADDY tomorrow
Why I YOLO'd my life savings on Mind Medicine and Why You Should Too
CMPS is moving on news it beat the leading Antidepressant in a study released yesterday. Hedge Funds shorted the stock ahead of the new.. morons.
$CMPS - New England Journal of Medecine - Clues about promising results, publication at 10pm London time
$CMPS - New England Journal of Medicine - Study to be published tonight at 10pm London time, clues about promising results.
Psilocybin Mushrooms / Alternative Mental Health Industry
Hunter Biden says psychedelic toad venom kept him sober for a year (good news for CMPS and other psychedelic stocks).
Roth Capital initiated coverage on Compass Pathways PLC (NASDAQ:CMPS) with a Buy rating and price target of $88 (currently at 37.50)
CMPS pathways GRANTED new patent for Major Depressive Disorder (previous grant was treatment resistant depression). 6.8 billion dollar market. Use of magic mushrooms for depression.
CMPS - This is just the start. Tiny compared to where we are going with the Psychedelic Renaissance
DD for CMPS (Compass Pathways) - Sorry it's posted as an image.
DD for CMPS (Compass Pathways) - Sorry it's posted as an image.
DD for CMPS (Compass Pathways) - Sorry it's posted as an image.
Shroom Stocks are Just Getting Started! CMPS | MMED | NUMI
Mentions
Psychedelic therapeutic stocks, ATAI and CMPS also doing well past year after taking big dumps post IPO. Lots of trials in the works and potential for big boys to scoop them up.
Also not financial advice but look into UNCY and CMPS if you want some semi-casino but huge upside plays, got all my regard savings in there
"sub it seems like a casino where everyone’s too emotionally invested." That's every stock specific sub, pretty much. People want their echo chamber where everyone agrees with them. I remember when there weren't any stock specific subs, now there's countless. Some of that has spilled into subs like this, too - there's so much less of the back-and-forth discussions there used to be on here. People talk their book and if they ask for opinions, so many times it's clear that they only want to hear positive ones. SMRs are interesting but you have something like OKLO where you won't have a reactor until 2027 and there are massive energy needs today. Inevitably, with stuff like this there's going to be a lot of low quality speculative stuff that is maybe going to be minimally successful or not at all. Maybe there's one or two eventual successes, but people get so far ahead of themselves that along the way the stock craters because it should have never been where it was in the first place - and you've seen that with OKLO. I remember when shroom stocks were soaring in 2020/21 because people were talking as if everyone was going to be using them as therapy tomorrow. CMPS went to 50 and it's now 5. Not a fan of the EV theme, but RIVN going public at $100B valuation without having delivered a car. Since covid, investing has been highly, highly focused on narratives. Some of these narratives work out really well. Some of them get way ahead of the reality or simply overhype something that wasn't a sustainable business in the first place. I remember when BYND ipo'd and people were talking on here as if that was all everyone was going to eat in the future when the stock went to $200+. It's now 64 cents a share.
My view, there are two companies with more advanced pipeline. CMPS will likely be approved this year and ATAI is 2-3 years behind.
I'm up 50% on drugs and war kTOS, RTX, DFTX , CMPS
Or $ATAI if you're worried about FOMOing into $CMPS. I'm about 80-20 $ATAI $CMPS. $CMPS will likely be first to market but $ATAI short acting psychedelics to compete with Spravato ketamine is where the money's at.
CMPS Psychedelic TRD treatment that will most likely get FDA approval. Told the group here Feb 13th here got laughed at and told to stfu. It’s up 35% since I posted and a mod took it down.
CMPS going to rip. Mushroom treats depression which is about to sky rocket
AI slop Been tracking Compass Pathways ($CMPS) for a while and the narrative has shifted pretty noticeably this week. For anyone not super familiar, Compass is a clinical-stage mental health biotech focused on developing COMP360, a synthetic psilocybin therapy for treatment-resistant depression (TRD) and other psychiatric indications. Back in the psychedelic stock boom of 2021, a lot of names ran hard and fast — $CMPS was no exception. Shares traded well above $40 and even near $50-plus at highs as hype around psychedelic therapeutics took off. But like many biotechs with long regulatory paths, it didn’t translate into a straight shot higher. By 2022 and 2023, the stock had fallen off sharply — by the end of 2022 it was down into the single digits, and into 2024-2025 it even hit low-$3-range territory at times. The reason for that multi-year sideways/low-price action was pretty simple: long clinical timelines and delayed catalysts. Psychedelic stocks in general didn’t have a staffed commercial product — and regulatory processes are slow — so prices reflected that uncertainty instead of any real revenue. Where things change is now. Today, Compass announced that the second pivotal Phase 3 trial (COMP006) for COMP360 in TRD met its primary endpoint with statistically significant improvement versus control, and a clean safety profile. The stock jumped because of this — reports showed shares up by roughly 40-45% on the day after the news. This matters because unlike a lot of speculative names that never showed definitive controlled data, Compass is now delivering late-stage signals you can actually build a regulatory story around. Previous phase 2 data had already shown meaningful clinical responses, which is part of why the FDA gave COMP360 Breakthrough Therapy designation earlier. That essentially acknowledges the unmet need in TRD and the potential for psyilocybin to be a real treatment option instead of theoretical. If you zoom out on the why this could be bigger long term, a few points stick out: TRD is a massive market with almost no FDA-approved options right now. Traditional antidepressants only work for some, and there’s a real gap for people who don’t respond to multiple therapies. Compare with ketamine/esketamine: J&J’s Spravato (esketamine) is approved and brings in billions annually because it’s a differentiated mechanism. Psilocybin could address a broader set of patients and has a different safety/effect profile. COMP360 doesn’t have the systemic toxicity risks associated with things like MDMA-based therapies, and MDMA isn’t even a classical psychedelic in the same sense. Analysts are still bullish on the name. There’s a consensus strong buy Yes, it’s still clinical-stage, no revenues yet, and biotechs carry binary risk — meaning if the next regulatory review doesn’t go well or if commercial execution stumbles, the stock can go the other way. But what just changed is that the biggest binary catalyst (phase 3 proof of concept) now has a positive outcome. That’s a straightforward reason for this renewed price action after years of sluggish trading. So if you’re thinking long term, the bull case isn’t just hope — it’s that Compass has moved from “maybe” to “data in hand,” and that’s the real thing investors were waiting for before this run.
Nice, CMPS killing it. This thing is going to 10x when it becomes mainstream.
YOLOing into CMPS. Phase 3 for treatment-resistant depression came in positive and the market definitely haven't priced in the implications for a first mover like them.
To all the CMPS holders.... Drinks are on me tonight.
#TLDR --- Ticker: CMPS Direction: Up (Long Term) Prognosis: Buy shares for a 2026/2027 binary play Drug: Synthetic Magic Mushrooms (Psilocybin) Risk Level: Lambos or Food Stamps (It goes to $0 if FDA denies)
MSFT, GOOG and then my mushy favorites CMPS, ATAI, DFTX
I wonder if that includes the TRD therapy. $CMPS
Why is CMPS dumping
I LOVE CMPS DOWN HERE: [https://x.com/ravagelaserbeak/status/2009716274507723113?s=20](https://x.com/ravagelaserbeak/status/2009716274507723113?s=20)
Buying as much CMPS as I can, been a great week so far, and I'm expecting at least another 50% or higher rally on the value in the coming weeks/months
LOVE $CMPS , THEY HAD THEIR COMMERCIALIZATION WEBCAST TODAY, PLUS FDA APPROVAL FOR PTSD INDICATION, TOPLINE PHASE THREE DUE IN Q1 OF 2026 , MORE HERE: [https://x.com/ravagelaserbeak/status/2008965697968472188?s=20](https://x.com/ravagelaserbeak/status/2008965697968472188?s=20)
Research the M&A that happened in the last year, you’ll see real money is flowing back and the valuations are rising. To name a few tickers I personally mentioned here this year: OBIO (at 2.40), ATAI (at 2.05), CMPS (~3), MRVI (2.20), all had even higher highs. The only one of those I’m still holding is OBIO, but the stock I’m really high and long on is DRTS
Amzn, ASTS, SOFI, Watch SLS and CMPS as they advance through trials and approval— multi baggers
I put CMPS up and surprised it got that many upvotes tbh. I really do believe in it’s the year for psilocybin but it is risky… FDA is supportive tho! Met phase 3 endpoints. Just a matter of time
$CMPS, $ATAI, $CYBN - Psychedelic medicine is the mental health breakthrough the world needs.
97% of my portfolio is VOO but 3% are my fun individual stocks and I will continue to buy psychedelic industry stocks. MNMD, ATAI, CMPS etc
Patented synthetic psilocybin polymorph (unique crystalline structure) going through FDA clinical trials. It's currently in the second Phase 3 trial, the final stage before potential approval. On top of that you have bipartisan support in Congress, RFK Jr publicly advocating for it, and the head of the FDA himself has said we need to be looking into these compounds. Lastly, FIVE of these compounds now have Breakthrough Therapy designation which further accelerated approval and massively raises approval chances. Psychedelic Drugs with FDA Breakthrough Therapy Designation 1. CYB003 (Deuterated Psilocybin analog) - $CYBN (soon to be $HELP) A novel psilocybin-derived compound developed by Cybin for major depressive disorder (MDD). Received Breakthrough Therapy designation from the FDA. Designed to have a faster onset and shorter duration than classic psilocybin. Currently in advanced clinical trials (Phase 3) for MDD. � Wikipedia +1 2. MM120 (LSD-based compound) - $MMED A specially formulated LSD-derived drug being developed by MindMed for generalized anxiety disorder (GAD). Granted Breakthrough Therapy status based on promising clinical data. � Forbes 3. Psilocybin (COMP360; various formulations) - $CMPS Psilocybin itself has received Breakthrough Therapy designations through specific company programs (e.g., COMPASS Pathways’ COMP360 for treatment-resistant depression and Usona Institute’s psilocybin program for major depressive disorder). These designations date back to earlier in the decade and continue to support ongoing Phase 3 research. � Grass Roots NLP +1 4. 5-MeO-DMT (BPL-003) - $ATAI A novel intranasal formulation of 5-MeO-DMT developed by Atai Life Sciences and Beckley Psytech has recently been reported to receive FDA Breakthrough Therapy designation for treatment-resistant depression. This reflects growing interest in rapid-acting psychedelic treatments beyond psilocybin and LSD. �
At least for CMPS, it's essentially psilocybin for treatment resistant depression, PTSD, etc.
Yeah but RFK is making it happen plus there's now the FDA expedited approval process. I still expect it to be more like 2027 just because there are some FDA higher ups who are cautious about psychedelics and that's how these things go, but 2026 is still going to be a great year for CMPS and friends. CMPS is my brightly colored, wavy, psychedelic horse. Already up 30% this year.
Been slowly increasing my holdings in $CMPS, am looking for this to 🚀 in 2026 and beyond, especially with all the positive results coming from clinical trials
Psychedelic medicine should have a massive year, especially if Compass' lead candidate gets FDA approval. $CMPS $ATAI $HELP
I’ve seen this drop with other preclinical companies too, like CMPS- data met endpoints in Phase 3 but then stock dropped. This is classic buy rumor sell news aka RUG PULL
nothing about being a biotech investor is fun - it's incredibly volatile, and the market makes contrarian moves against you constantly. my firms are all rated buy, they have high price targets, and are very close to FDA approval - however, those green lights mean nothing - the stocks dump on positive data, on c;lear prospects for approval, on patent upholds, even on special meetings w/ RFK to win the panel over (CMPS / Comp360), it dumps on literally everything - i can only hope the market will become more favorable in a low interest environment, but as it stands, the sector is controlled by short sellers, and doesn't seem to be changing any time soon.
Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months CMPS up 12% pre market 🤌
Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months CMPS up 10% in PM 🤌
CMPS gonna retest new high of day soon hop innnn
What will CMPS and NVO earnings bring this week 😬
Why MNMD and not CMPS?
BTIG analyst Thomas Shrader maintains Compass Pathways ( CMPS ) with a Buy and raises the price target from $7 to $14.
Damn I thought CMPS would get granted first.
I think of you every day when I check my investment account and see it up by another $25k. +$600k and counting between ATAI and CMPS
CMPS (Compass Pathways). Multiple late stage clinical trials with psychedelics and waiting on FDA approval for treatment resistant depression. Largest drop recently is because investors thought the effectiveness of their recent Phase 3 would be higher. It’s since completely bounced back to above those levels.
Really enjoy finding promising, innovative biotech companies. Today I like Compass (CMPS) that is working with complex drugs to treat depression. Any thoughts?
The volume on psychedelic stocks is crazy. PSIL ATAI CMPS CYBN are bout to blow
Psychedelic approvals must be coming with this volume ATAI PSIL CMPS CYBN
Don’t sleep on shroom stocks with all the data coming and the work with RFK’s FDA. CMPS and ATAI lead the pack.
Continuing to buy psychedelic stocks, per usual. PSIL ATAI CYBN CMPS
Psychedelics approval is all but guaranteed with this administration and you’re going to miss the boat ATAI CYBN CMPS PSIL
Shroom stocks beating the odds today ATAI CYBN CMPS
I like what you are saying. I also believe CMPS is set to sky rocket.
Daily shroom stock shill CMPS CYBN
I believe it is CMPS all the way.
CMPS and CYBN help my IRA reach enlightenment
CMPS is going to do that good
I hold 5k shares of Mind Medicine and 5k shares of CMPS at $5.94 and $3.32 averages respectively :) But pot is the swing trade right now.
Trimming REITs (office space is already empty and a recession (caused by Ai and national and geopolitical turmoil) will drive more traditional companies with office space into bankruptcy and cause them to default on their lease -- I hope I'm wrong). Long term holdings (not adding) MNMD, ATAI, CMPS and a small one CMND. New-to-me long term holdings that I intend to add more off LLY, NVO, TSLA, CRCL, APP, PANW, FTNT).
CMPS will pull you out of the galaxy.
Yeah that's fine, but even better is CMPS to 45.00
CMPS is on it's way to 45.00 a share.
I can't wait for CMPS to hit 45.00
Psychedelics are the next wave. $CMPS
also it seems ATAI is selling CMPS major product, COMP360.
ATAI lowered their stake I followed their lead. I'm not against CMPS. But since ATAI still owns a portion I'm diversified to a degree.
Because i am a retard, i will short ATAI and CMPS today
Most of them are crap. ATAI, MNMD and CMPS will be the horses here. ATAI never went through its cycle. MNMD was shit until the new CEO took over, CMPS only because CYBN is a joke.
So I should hold? Put everything in NVNI because I thought it would bounce back past 0.7. But is this more a long term play? I was hoping for a quick rise so I could sell a bit and diversify. Put some money into MBOT and IXHL. As well as the psych therapy sector, like ATAI, MINDMED and CMPS. So when do you think we’ll see some news? Like a possible buyout, acquisition or oracle partnership? Really hope it doesn’t tank, that would suck.
Psychedelic biotechs like MNMD and ATAI are having a moment too - maybe CMPS soon... MNMD is finally on the up
Well explained DD’s, Reddit posts and such. Sadly it’s 99% luck. IMO, CMPS is next to pump. I’m buying calls tomorrow morning
"I've heard that I should wait to buy after 8/1 due to the US tariff situation." People don't wait for certain dates to react to something. They take it into account when they hear about it, consider how likely it is, etc. There has been so much focus on tariffs while the market is up 26% off the April low. There will absolutely be a correction at some point and I wouldn't be surprised if that correction is due to something other than tariffs. "Other stocks im currently interested in are CRSP ONDS JOBY AMPX" I think one has to realize that we're back in a sort of 2020/21 environment where evvvverrrrryyyyone wants to own the RKLB, ASTS, PLTR, etc stocks that go up every day. That works until it doesn't and there is a point where it stops being about valuation or anything correlated to where the company is, it's just pure FOMO chasing. You had a period in 2020/21 where people acted as if a lot of stories were going to happen tomorrow when the stories were going to happen maybe in 5+ years if not much longer. CMPS is a great example - shroom stocks, which was a big topic on here at the time. CMPS IPO'd, went up about 100% in a short time then proceeded to lose about 92% in the years since. BYND was a nearly $250 stock at one point now it's $3.50. Not saying that RKLB or ASTS are bad stocks (I am long both but from much lower levels), but all of this sort of early/earlier stage stuff there is something to the idea that the stocks can get ahead/far ahead of where the companies are and when the music stops it looks like 2022 or early 2025. RKLB is up 105% YTD, but when the market tanked earlier this year it lost nearly 50%. The music will stop at times and if you have a portfolio full of speculative/very speculative stocks, don't be surprised when it's down 30-40-50% in a hurry. "I don't want to miss out on potential gains and get major FOMO" ASTS is up 150% since the end of May. It's already FOMO at this point. Given age it's good to have risk, but you want to allocate risk in a way that is sustainable - if another early 2025 happened tomorrow and you had a portfolio full of stuff like this "CRSP ONDS JOBY AMPX" would you dump it all? How do you allocate in a way that gets you through good times in the market and shitty times because there's going to be lousy days/weeks/months and years (2022 wassn't that long ago.)
yeah i'm holding some CMPS for sentimental reasons, like that one summer i did acid every other day in 1990. good times.
MNMD or ATAI with their BioPharm stuff. MNMD got a breakthrough therapy designation for Generalized Anxiety Disorder on their MM120 drug from the FDA not long ago and was already working with consultants on how to approach their phases. And now, the FDA just changed their ways and said that instead of just telling companies they failed the phases/tests/approval, they are now telling them EXACTLY why they failed. So, in the terms of these BioPharm companies that have been working to get their drugs approved and to the market, they know will have sufficient information to go back on should they fail in their approvals. MNMD seems to be the champion here right now as their growth is actually not too bad for a company with no drugs to the market just yet. There have been expansions in the company's size, they have worked with consultants from the FDA, from a variety of healthcare industry leaders, and also Big Pharm companies. ATAI is a similar company, using a different compound for GAD and social anxiety. However as of now I think they are in the process of phase 2, where as MNMD is in phase 3 with one pipeline and almost done 2 with another. I'm sure these 2 have been tossed around in the likes of Compass (CMPS) and Cybin Inc (CYBN) although I think CYBN might be out of the picture and working on patents in England last I heard? Don't quote me. I have really been watching MNMD for years and more recently paid attention to ATAI. I think this sector is getting a ton of attention now with veterans speaking out of their experiences with psychoactives and therapy. The government is loosening up it's grip and is seeing this as an industry. Both are cheap enough to get a few shares, stash, see what they move like and evaluate your position in a year.
Peter Thiel backed with an interesting spoke and wheel business model in a Trump/RFK supported industry. It's up ~100% ytd but has lots of room to run if phase 3 trial data turns positive and the White House/FDA remains pro-psychadelic. CMPS is another lotto ticket in a potentially lucrative sector.
Nice I got 1,620 shares of CMPS that I need to explode!
Of course nobody has only wins, but u/pristine_hurry_4693 has given me BBAI at 2.71, OBIO that moved a bit, MRVI that is down this week but he’s been onto it since about 2$, SRFM, said CMPS will bounce back after it recently got cut in half, ATAI which is the same category, he got me onto Quantum, he’s been preaching Bitcoin since 34K (at least that’s when I heard it from him), I got the CYN run and MLGO (even though that one I miss timed), you get the point… of course I use my own discretion and lately he’s harping on DRTS only, but he’s good
And CMPS for that matter
Asps is a pretty good bet if we go into a recession. I love CMPS since it crashed. Robert Kennedy will push CMPS and MNMD into fda approval. The overall market is overpriced, so these tariffs are definitely not going to help. Powell is not going to cave in like Trump so this is going to be interesting. Buckle io
I hold some shares in CMPS They're in the psychedelic therapy space with a psilocybin drug and treatment protocol. Primarily, I want to support them. It would also be great to make a few bucks on it eventually
I have 10k shares @ .456 cost. I got in early to this one thanks to following terpstrader1 on webull. He has about 500k in pmax at a higher cost because he was in a bit earlier than me and I caught a dip. Already up 17% and I ain't selling! I also got into CMPS because of him and made 2.6k
CMPS took a 50% hit last week after releasing a sneak peak to the results to the phase 3 clinical trials. The results were good, but not mind shattering like the stockmarket wanted. Sure the price target may have dropped, but it's a steal at $2.70/share. Especially with how friendly the administration is with physchedlic assisted therapy.
I like BBAI Other than that CMPS showed a start of a comeback after getting cut in half this week CYN spiked as it tends to do lately between 4 and 5 And not necessarily short term but I’m holding DRTS with strong conviction and high hopes
CMPS still recovering from its drop
CMPS is showing signs of life after its drop. Keep an eye on it
$CMPS and $NXPL for that bottom bounce also